Simonetti, G.(2018). Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation. Blood, 132(Supplement 1), 2639-2639. doi:10.1182/blood-2018-99-117429
MLA ZitierstilSimonetti, Giorgia. "Alternative Overexpression of NRF2 or MYC Defines a Subgroup of Poor Prognosis Acute Myeloid Leukemia and Suggests a Novel Therapeutic Strategy By Combined Bromodomain Inhibition and Forced NRF2 Pathway Activation". Blood, 132.Supplement 1 ( 2018 ): 2639-2639.
Bitte überprüfen Sie diese Angaben auf Richtigkeit, bevor Sie sie in Ihre Arbeit aufnehmen.